Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study.

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study.

Item
http://www.wikidata.org/entity/Q33830219
Bone and TNF in rheumatoid arthritis: clinical implicationsEffects of anti-tumor necrosis factor α agents on boneBiologic therapies and bone loss in rheumatoid arthritis.Hand bone mass in rheumatoid arthritis: A review of the literatureInitiation of tumor necrosis factor α antagonists and risk of fractures in patients with selected rheumatic and autoimmune diseasesBone effects of biologic drugs in rheumatoid arthritis.Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.Disease Activity and Bone Mineral Density of MCP Joints in Patients with Rheumatoid and Psoriatic Arthritis: Is There a Correlation?-A Study in Patients Treated with Methotrexate and an Anti-TNF α Agent.The Impact of Conventional and Biological Disease Modifying Antirheumatic Drugs on Bone Biology. Rheumatoid Arthritis as a Case Study.Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial.Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.Role of glucocorticoid-induced leucine zipper (GILZ) in inflammatory bone loss.Opioid Use and Risk of Nonvertebral Fractures in Adults With Rheumatoid Arthritis: A Nested Case-Control Study Using Administrative Databases.Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Rheumatoid Arthritis.Decreased quantity and quality of the periarticular and nonperiarticular bone in patients with rheumatoid arthritis: a cross-sectional HR-pQCT study.Biologic disease-modifying anti-rheumatic drugs and the risk of non-vertebral osteoporotic fractures in patients with rheumatoid arthritis aged 50 years and over.Association of Low Bone Mineral Density with Anti-Citrullinated Protein Antibody Positivity and Disease Activity in Established Rheumatoid Arthritis: Findings from a US Observational Cohort.
P2860

Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: subanalysis of the PREMIER study.

Item
http://www.wikidata.org/entity/Q33830219
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@ast
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@en
type
label
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@ast
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@en
prefLabel
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@ast
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Adalimumab reduces hand bone l ...... analysis of the PREMIER study.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932